Park: Econometric Theory, volume 45, pages 73-95, " Asymptotic Properties of the Least Squares Estimator in Local to Unity Processes with Fractional Gaussian Noise,"Īdvances in Econometrics, in: Essays in Honor of Joon Y. Xiaohu Wang & Weilin Xiao & Jun Yu, 2023.Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. 2001 33:1358–1364.īochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F Swiss Hepatitis C Cohort Study Group. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. 2014 61:S45–S57.Īdinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Global epidemiology and genotype distribution of the hepatitis C virus infection. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global distribution and prevalence of hepatitis C virus genotypes. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Published by Baishideng Publishing Group Inc. Our findings suggest a limited role for RBV as routine add-on therapy to SOF/VEL in GT3 compensated cirrhosis patients.Ĭirrhosis Direct-acting antiviral Hepatitis C Sofosbuvir/velpatasvir. Ribavirin was not associated with higher SVR12 in GT3 compensated cirrhosis patients receiving SOF/VEL. However, addition of RBV did not significantly increase the SVR12 among treatment-experienced GT3 compensated cirrhosis patients. Subgroup analysis showed that RBV was associated with a higher SVR12 in GT3 compensated cirrhosis patients with baseline resistance-associated substitutions. Addition of RBV increased the pooled risk of treatment-related adverse events in GT3 compensated cirrhosis patients receiving SOF/VEL (RR: 4.20, 95%CI: 1.29-13.68 I 2 = 0%). The overall pooled rate of treatment-related adverse events was 7.2%. The SVR12 was similar in GT3 compensated cirrhosis patients, regardless of the use of RBV, for both the intention-to-treat RR 1.03, 95%CI: 0.99-1.07 I 2 = 0%) and the per-protocol analysis (RR: 1.03, 95%CI: 0.99-1.07 I 2 = 48%). The pooled relative risk (RR), 95%CI and heterogeneity ( I 2) were estimated using Review Manager version 5.3.įrom 1752 citations, a total of seven studies (2 randomized controlled trials, 5 cohort studies) with 1088 subjects were identified. The secondary outcome was treatment-related adverse events, as defined by symptomatic anemia requiring transfusion or a drop in hemoglobin beyond 2 g/dL. The primary outcome was sustained virological response 12-wk post-treatment (SVR12). All GT3 compensated cirrhosis patients treated with 12 wk of SOF/VEL, with or without RBV, were included, regardless of age, gender or prior treatment experience. There was no restriction on language, geography, publication dates and publication status (full text or abstracts). We searched four electronic databases (PubMed/Medline, Embase, Cochrane Library and Web of Science) from inception up to June 2021 using both free text and MeSH terms. To evaluate the efficacy and safety of SOF/VEL, with or without RBV in GT3 compensated cirrhosis patients. While the addition of ribavirin (RBV) to SOF/VEL improved sustained virological response (SVR12) in genotype 3 (GT3) decompensated cirrhosis patients, the benefits of RBV in GT3 compensated cirrhosis patients receiving SOF/VEL remains unclear. Sofosbuvir/velpatasvir (SOF/VEL) is an effective pan-genotypic direct-acting antiviral combination for treatment of chronic HCV infection. Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and hepatocellular carcinoma globally.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |